Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
europe blog main
3
×
europe top stories
fda
3
×
life sciences
national blog main
boston blog main
boston top stories
national
national top stories
san francisco blog main
san francisco top stories
abaloparatide
abbvie
alkermes
allergan
amgen
arena pharmaceuticals
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
eisai
eli lilly
europe
european commission
felipe jain
indiana blog main
indiana top stories
jess fiedorowicz
jessica jeffrey
karim calis
lorcaserin
lumateperone
What
drug
medicine
3
×
fda
marketing
weight
alkermes
amgen
amgen’s
antipsychotic
approval
benefits
cancer
carries
caveats
commonly
designed
developed
effect
eisai
europe
european
favor
flags
gain
heart
higher
incidence
lorcaserin
loss
market
nod
offer
osteoporosis
panel
patients
post
prescribed
psyche
pulls
raise
Language
unset
Current search:
fda
×
biotech
×
" europe blog main "
×
medicine
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning